Guess what, the multitudes of other companies that have invested millions or a billion into the next best Alzheimers treatment felt really great about their drug too early on. I bet scientists that ran 38 clinical trials for bryostatin to treat cancers and HIV felt really optimistic that the trials would be successful too.
The Ph 2b was originally planned to be 6 months long, but then Neurotrope amended it to just be 3 months long. Seems they doubted scores would hold up long term. Neurotrope will announce good results in April. This board will be going ga ga, intoxicated that Neurotrope is gonna be the next REGN or Acadia. Sustain good scores for a year or more, then we'll talk. Neurotrope is gonna run a PH 3 based on just a 3 month trial? Highly irregular.
News 
Market Data 
Discover 
